FIELD: pharmaceuticals.
SUBSTANCE: group of inventions relates to the pharmaceutical industry, namely, to an application of an agent for preventing, alleviating, or treating a Coronavirus-19 infection (SARS-CoV-2). Application of an ethanol extract of Elaeocarpus sylvestris leaves for preventing, alleviating, or treating a Coronavirus-19 infection (SARS-CoV-2), wherein the ethanol extract of Elaeocarpus sylvestris leaves has an inhibitory effect on the replication of the SARS-CoV-2 virus. Application of the pharmaceutical composition containing an ethanol extract of Elaeocarpus sylvestris leaves as an active component and a pharmaceutically acceptable carrier, an auxiliary substance or diluent, for preventing, alleviating, or treating a Coronavirus-19 infection (SARS-CoV-2), wherein the ethanol extract of Elaeocarpus sylvestris leaves has an inhibitory effect on the replication of the SARS-CoV-2 virus.
EFFECT: application of the above extract and composition is effective for preventing, alleviating, or treating a Coronavirus-19 infection (SARS-CoV-2).
5 cl, 3 dwg, 2 tbl, 7 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PREVENTION OR TREATMENT OF CORONAVIRUS AND OTHER ACUTE RESPIRATORY VIRAL INFECTIONS | 2022 |
|
RU2794315C1 |
NEW APPLICATION OF NATURAL DOUBLE-STRANDED RNAS FOR THE TREATMENT AND/OR PREVENTION OF VIRAL INFECTIONS | 2022 |
|
RU2781903C1 |
METHODS OF TREATING CORONAVIRUS INFECTIONS | 2021 |
|
RU2825648C1 |
PEPTIDE IMMUNOGENS AND A VACCINE COMPOSITION AGAINST CORONAVIRUS INFECTION COVID-19 USING PEPTIDE IMMUNOGENS | 2020 |
|
RU2738081C1 |
METHOD FOR THE TREATMENT OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2021 |
|
RU2775966C1 |
5'-O-(3-PHENYLPROPIONYL)-N4-HYDROXYCYTIDINE AND ITS APPLICATION | 2022 |
|
RU2791523C1 |
WHOLE VIRION INACTIVATED VACCINE AGAINST SARS-Cov-2 INFECTION AND ITS USE | 2023 |
|
RU2809375C1 |
AGENT FOR REDUCING RISK AND RELIEVING SYMPTOMS OF BETA-CORONAVIRUS INFECTION | 2021 |
|
RU2747890C1 |
COMPOSITION FOR INCREASING THE RESISTANCE OF THE ORGANISM TO THE NEW CORONAVIRUS INFECTION COVID-19 | 2021 |
|
RU2774831C1 |
PHILLYRIN AND ITS DERIVATIVES FOR SUPPRESSION OF THE 3CLPRO PROTEIN AND FIGHTING THE COVID-19 VIRUS | 2021 |
|
RU2804307C1 |
Authors
Dates
2022-09-21—Published
2021-01-11—Filed